“Don’t write that we have a cure for cancer tomorrow,” says Pascal Soriot, chief executive of AstraZeneca, “but there are some spectacular results.”
Mr Soriot was at MedImmune on Granta Park, AstraZeneca’s current toe-hold on the city and on the day that the pharma company announced its chosen site – Cambridge Biomedical Campus at Addenbrooke’s – to relocate its global HQ and UK R&D activities.